Adjuvant aromatase inhibitors for breast cancer

Lancet

Volumn 366, Issue 9484, 2005, Pages 431-433

  Howell, Anthony ^a  

^a CHRISTIE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; EXEMESTANE; LETROZOLE; TAMOXIFEN;

ARTHRALGIA; BREAST CARCINOMA; CANCER SURVIVAL; CLINICAL TRIAL; DRUG EFFICACY; DYSPAREUNIA; EVALUATION; FRACTURE; GYNECOLOGIC DISEASE; HOT FLUSH; HUMAN; NOTE; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; SIDE EFFECT; THROMBOEMBOLISM; TUMOR RECURRENCE; VAGINAL DRYNESS;

EID: 23444458199     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(05)67036-5     Document Type: Note

References (14)

1. R Jakesz, W Jonat, M Gnant Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial Lancet 366 2005 455 462
2. Howell A, Cuzick J, Baum M The ATAC Trialists' Group Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer Lancet 365 2005 60 62
3. B Thurlimann, A Kesaviah, H Mouridsen BIG 1-98: Randomized double-blind phase III study to evaluate letrozole (L) vs. tamoxifen (T) as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer Proc Am Soc Clin Oncol 23 2005 6S (abstr)
4. RC Coombes, E Hall, CF Snowdon, JM Bliss The Intergroup Exemestane Study: a randomised trial in postmenopausal patients with early breast cancer who remain disease-free after two to three years of tamoxifen - updated survival analysis Breast Cancer Res Treat 88 2004 S7 (abstr)
5. F Boccardo, A Rubagotti, M Puntoni Switching to anastrozole versus continued tamoxifen treatment of early breast cancer. Preliminary results of the Italian Tamoxifen Anastrozole (ITA) trial J Clin Oncol 2005 10.1200/JCO.2005.04.120 published online July 11
6. P Goss, J Ingle, S Martino Updated analysis of the NCIC CTG MA.17 randomized placebo (P) controlled trial of letrozole (L) after five years of tamoxifen in postmenopausal women with early stage breast cancer Proc Am Soc Clin Oncol 22 2004 847 (abstr)
7. R Jakesz, H Samonigg, R Greil Extended adjuvant treatment with anastrozole: results from the Austrian Breast and Colorectal Cancer Study Group Trial 6a (ABCSG-6a) Proc Am Soc Clin Oncol 23 2005 10S (abstr)
8. Early Breast Cancer Trialists' Collaborative Group Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials Lancet 365 2005 1687 1717
9. J Cuzick, P Sasieni, A Howell. Should aromatase inhibitors be used as initial adjuvant treatment or sequenced after tamoxifen? Br J Cancer (in press).
10. RS Punglia, KM Kuntz, EP Winter, JC Weeks, HJ Burstein Optimising adjuvant endocrine therapy in postmenopausal women with early stage breast cancer: a decision analysis J Clin Oncol 2005 10.1200/JCO.2005.02.964 published online July 5
11. CK Osborne, R Schiff Aromatase inhibitors: future directions Steroid Biochem Mol Biol 2005 10.1016/j.jsbmb.2005.04.021 published online July 11
12. RJ Santen, RX Song, Z Zhang Adaptive hypersensitivity to estrogen: mechanisms and clinical relevance to aromatase inhibitor therapy in breast cancer treatment Steroid Biochem Mol Biol 2005 10.1016/j.jsbmb2005.04.025 published online July 11
13. GJ Sabnis, D Jelovac, B Long, Brodie A The role of growth factor receptor pathways in human breast cancer cells adapted to long-term estrogen deprivation Cancer Res 65 2005 3903 3910
14. D Jelovac, L Macedo, OG Goloubeva, V Handratta, AM Brodie Additive antitumour effect of aromatase inhibitor letrozole and antiestrogen fulvestrant in a postmenopausal breast cancer model Cancer Res 65 2005 5439 5444